Hydroxychloroquine — sold under the brand name Plaquenil — is a malaria drug that has been used to treat lupus for decades, and the clinical evidence supporting it is not subtle. A meta-analysis of 21 studies covering more than 26,000 patients found that hydroxychloroquine reduced overall mortality in systemic lupus erythematosus by approximately 54 percent. That is not a marginal benefit. It is the kind of result that has led every major rheumatology guideline to recommend that all SLE patients receive the drug unless they have a specific contraindication. The roots of this treatment run even deeper than most people realize.
Quinine, the antimalarial compound from which hydroxychloroquine descends, was first used to treat cutaneous lupus in 1834 — giving this drug class nearly 200 years of lupus-related use. Hydroxychloroquine sulfate itself was synthesized in 1946 and received FDA approval on April 18, 1955. Today it sits on the World Health Organization’s List of Essential Medicines and remains one of the most affordable treatments available. In 2023, it was the 131st most commonly prescribed medication in the United States, with more than 4 million prescriptions filled. This article examines the specific clinical trials that built the case for hydroxychloroquine in lupus, the survival data that made it a cornerstone of treatment, who lupus affects most, what the safety tradeoffs look like — particularly for the eyes — and what current guidelines say about dosing and monitoring.
Table of Contents
- Why Is a Malaria Drug Used for Lupus, and What Evidence Backs It Up?
- How Much Does Hydroxychloroquine Reduce Mortality in Lupus Patients?
- Who Gets Lupus, and Why Hydroxychloroquine Access Matters
- Current Dosing Guidelines and What Every Patient Should Know
- The Eye Risk — What Updated 2025 Screening Guidelines Say
- Hydroxychloroquine During Pregnancy and Lupus Flare Prevention
- What Decades of Data Mean for the Future of Lupus Treatment
- Conclusion
- Frequently Asked Questions
Why Is a Malaria Drug Used for Lupus, and What Evidence Backs It Up?
The short answer is that hydroxychloroquine modulates the immune system in ways that happen to be useful for both malaria and autoimmune disease. In lupus, the immune system attacks the body’s own tissues, causing inflammation in the joints, skin, kidneys, and other organs. Hydroxychloroquine dampens that overactive immune response, reduces flares, and allows patients to lower their steroid doses — which matters because long-term steroid use carries its own serious risks. The drug also has antithrombotic effects, meaning it helps prevent blood clots, a common and dangerous complication in lupus patients who carry antiphospholipid antibodies. The landmark clinical trial came in 1991, when the Canadian Hydroxychloroquine Study Group published a randomized controlled trial in the New England Journal of Medicine. They took 47 SLE patients who were stable on hydroxychloroquine and randomly assigned some to stop taking it. The results were stark: patients who discontinued the drug had a 2.5-fold higher risk of clinical flare compared to those who continued.
Sixteen out of 22 patients who stopped the drug flared, versus 9 out of 25 who stayed on it. This was the first randomized controlled trial of antimalarials in SLE, and it changed clinical practice. A long-term follow-up published in 1998 extended the findings: over 42 months, 50 percent of those who stopped hydroxychloroquine experienced a major flare, compared with 28 percent who continued — a relative risk of 0.43 for major flare with continued use. A systematic review published in the Annals of Rheumatic Diseases in 2009 analyzed 95 articles spanning 1982 to 2007. It found strong evidence that hydroxychloroquine decreased lupus disease activity, including during pregnancy without fetal harm, and moderate evidence that it protected against irreversible organ damage, thrombosis, and bone mass loss. By comparison, many drugs that receive widespread attention have far thinner evidence behind them. Hydroxychloroquine earned its place through volume and consistency of data over decades.
How Much Does Hydroxychloroquine Reduce Mortality in Lupus Patients?
The mortality data is what elevates hydroxychloroquine from a helpful drug to a potentially life-saving one. A 2022 meta-analysis pooling 21 studies and 26,037 patients found that hydroxychloroquine use was associated with a pooled hazard ratio of 0.46 for overall mortality — roughly a 54 percent reduction in the risk of death. Three prior cohort studies from tertiary referral centers had individually reported a 38 to 85 percent reduction in overall mortality with hydroxychloroquine use, and the meta-analysis brought those findings into sharper focus. The drug also appears to protect against serious infections. Subgroup analyses showed that hydroxychloroquine significantly prevented serious infections, with an odds ratio of 0.40 and a 95 percent confidence interval of 0.25 to 0.64. For a disease that is treated primarily with immunosuppressive drugs — which inherently increase infection risk — having one medication that actually lowers infection rates while controlling disease activity is unusual and valuable.
However, stopping the drug carries its own risk. Research has shown a two-fold increased risk of death associated with recent hydroxychloroquine discontinuation compared with remote discontinuation. This means the protective effect is not permanent; it depends on sustained use. Patients who stop the drug abruptly, whether due to side effects, cost, or personal choice, face a measurable increase in danger. This is a critical point for clinicians and patients to understand — hydroxychloroquine is not a drug you take for a course and then move on from. For most lupus patients, it is a long-term commitment.
Who Gets Lupus, and Why Hydroxychloroquine Access Matters
systemic lupus erythematosus affects an estimated 204,295 Americans, according to CDC national lupus registries. The disease is nine times more common in females than males, and it strikes some communities far harder than others. The highest rates are among Native American and Alaskan Native women, at 270.6 per 100,000, followed by Black women at 230.9 per 100,000, Hispanic women at 120.7 per 100,000, and White women. Overall, lupus is two to three times more prevalent among Black, Hispanic/Latina, Native American, and Pacific Islander women than White women. These disparities matter for hydroxychloroquine access because the communities hit hardest by lupus are often the same communities that face barriers to healthcare.
Hydroxychloroquine is inexpensive and widely available as a generic, which is one of its greatest strengths. But affordability of the pill means little if patients cannot access regular rheumatology care, ophthalmologic screening, and the kind of sustained follow-up that safe long-term use requires. A patient in a rural Native American community or an under-resourced urban neighborhood may have the prescription but lack the monitoring infrastructure to use it safely for years. The racial and ethnic patterns of lupus also intersect with a safety consideration discussed further below: retinal toxicity from hydroxychloroquine presents differently by ethnicity. European-heritage patients tend to develop a parafoveal pattern of damage, while East Asian patients more commonly show a pericentral pattern. Screening protocols that do not account for these differences risk missing early toxicity in certain populations.
Current Dosing Guidelines and What Every Patient Should Know
All major rheumatology guidelines now recommend that every SLE patient receive hydroxychloroquine unless there is a specific contraindication. This is supported by high-grade evidence, and the recommendation applies across disease subtypes — including lupus nephritis, cutaneous lupus, and during pregnancy and breastfeeding. The recommended dosage is no more than 5.0 mg/kg per day based on real body weight, with a cap of 400 mg per day for severely obese patients. The dosing cap matters because the risk of retinal toxicity — the most concerning long-term side effect — is dose-dependent. Patients who take higher doses relative to their body weight accumulate more risk over time. The shift toward weight-based dosing was a deliberate effort to balance efficacy against eye safety, and it represents a tradeoff.
Some patients, particularly smaller individuals, may need lower absolute doses than the traditional 200 or 400 mg tablets easily provide. Pill-splitting is sometimes necessary, and not all patients are told about this. Beyond flare prevention, hydroxychloroquine provides several secondary benefits that make it difficult to replace. It allows steroid dose reduction, which protects patients from the long-term effects of corticosteroids — weight gain, bone loss, diabetes, and cataracts. It reduces organ damage accumulation over time. And it prevents the thrombotic effects of antiphospholipid antibodies, which cause strokes and blood clots in a subset of lupus patients. No single alternative drug matches this combination of benefits at this cost.
The Eye Risk — What Updated 2025 Screening Guidelines Say
The most significant long-term risk of hydroxychloroquine is retinal toxicity, and the American Academy of Ophthalmology published updated screening guidelines in November 2025, approved in October 2025. The current recommendation calls for a baseline retinal exam within the first few months of starting the drug — primarily to rule out pre-existing macular disease — followed by annual screening after five years of use. The primary screening tools are macular optical coherence tomography and wide-pattern fundus autofluorescence. The risk factors for retinal toxicity are straightforward: higher dose, longer duration of use, concurrent renal disease or tamoxifen use, and older age at the time the drug is started. Patients who take hydroxychloroquine for more than five years at doses exceeding the recommended 5.0 mg/kg per day threshold are at the greatest risk.
However, even patients who follow all guidelines can develop toxicity, and the damage is generally not reversible. At the earliest stages, there is some possibility of stabilization or mild improvement after discontinuation, but severe cases may continue to worsen for years after the drug is stopped. This is the central tension of hydroxychloroquine therapy: the drug that reduces mortality by 54 percent and prevents major organ damage can itself cause irreversible damage to one organ. The answer is not to avoid the drug — the survival benefit overwhelmingly favors continued use — but to screen consistently and catch toxicity early, when stopping the medication can still prevent progression. Patients who skip their eye exams are playing a dangerous game, and clinicians who prescribe without arranging monitoring are failing their patients.
Hydroxychloroquine During Pregnancy and Lupus Flare Prevention
One of the most reassuring findings from the evidence base is that hydroxychloroquine appears safe during pregnancy and breastfeeding. The 2009 systematic review found strong evidence that the drug decreased lupus activity during pregnancy without fetal harm. This is significant because lupus frequently affects women of childbearing age, and pregnancy itself can trigger lupus flares. Many immunosuppressive drugs used in lupus must be stopped before or during pregnancy, leaving patients vulnerable at precisely the time their disease may worsen.
Hydroxychloroquine fills this gap. A woman with lupus who becomes pregnant can generally continue her hydroxychloroquine, maintaining disease control while other medications are withdrawn. Stopping it, as the discontinuation studies show, increases the risk of flare — and flares during pregnancy endanger both mother and child. For this reason, current guidelines specifically endorse continued hydroxychloroquine use during pregnancy and lactation.
What Decades of Data Mean for the Future of Lupus Treatment
Hydroxychloroquine is unlikely to be displaced as a foundational lupus therapy anytime soon. The drug is cheap, effective, well-tolerated by most patients, available worldwide, and backed by nearly 200 years of clinical history in various forms. New biologic therapies like belimumab and anifrolumab have expanded the lupus treatment landscape, but they are expensive, require infusions or injections, and are typically added on top of hydroxychloroquine — not used instead of it.
The real frontier is not replacing hydroxychloroquine but improving how it is used: ensuring weight-based dosing is standard, making retinal screening accessible to all patients who need it, and closing the gap between who has lupus and who receives sustained treatment. For the estimated 204,295 Americans living with SLE, and the communities disproportionately affected by the disease, the challenge was never whether the drug works. The evidence settled that question decades ago. The challenge is making sure the right patients get it, stay on it, and are monitored while taking it.
Conclusion
Hydroxychloroquine is one of the best-supported treatments in rheumatology. From the first RCT in 1991 showing a 2.5-fold flare risk after discontinuation, through the 2022 meta-analysis demonstrating a 54 percent reduction in mortality across more than 26,000 patients, the evidence is deep and consistent. The drug prevents flares, reduces organ damage, lowers infection risk, allows steroid tapering, and is safe in pregnancy. Current guidelines recommend it for all SLE patients unless contraindicated, at doses not exceeding 5.0 mg/kg per day of real body weight.
The one serious long-term concern — retinal toxicity — is manageable with proper screening. The 2025 AAO guidelines call for a baseline eye exam early in treatment and annual monitoring after five years. Patients and clinicians who follow these protocols can catch toxicity early enough to prevent severe vision loss. For anyone living with lupus, hydroxychloroquine is not just another medication in the lineup. It is the backbone of treatment, and the decades of data behind it make that position difficult to argue against.
Frequently Asked Questions
Is hydroxychloroquine the same as chloroquine?
No. Hydroxychloroquine is a hydroxylated analogue of chloroquine, synthesized in 1946. It has a better safety profile than chloroquine, particularly regarding retinal toxicity, and is the preferred antimalarial for lupus treatment. Both drugs are in the same class, but they are not interchangeable.
Can I stop taking hydroxychloroquine if my lupus is well controlled?
The evidence strongly advises against it. The landmark 1991 trial showed a 2.5-fold increase in flare risk after stopping, and more recent research found a two-fold increased risk of death associated with recent discontinuation. Most rheumatologists recommend indefinite use unless a contraindication develops.
How long before hydroxychloroquine starts working for lupus?
Hydroxychloroquine is slow-acting. Most patients begin to notice improvement in symptoms after several weeks to a few months, but full benefit may not be apparent for three to six months. This is not a drug that provides immediate relief, which is why corticosteroids are often used alongside it in the short term.
Does hydroxychloroquine cause blindness?
Retinal toxicity is a real but manageable risk. The 2025 AAO guidelines recommend annual screening after five years of use. When caught early, stopping the drug can prevent progression. However, severe retinal damage from hydroxychloroquine is generally not reversible and may continue to worsen even after discontinuation. Consistent eye screening is essential.
Is hydroxychloroquine safe during pregnancy?
Yes. A systematic review of 95 articles found strong evidence that hydroxychloroquine decreased lupus activity during pregnancy without fetal harm. Current guidelines recommend continuing it during pregnancy and breastfeeding, as stopping increases the risk of disease flares that can endanger both mother and child.
How much does hydroxychloroquine cost?
Hydroxychloroquine is an inexpensive generic medication available worldwide. It is on the WHO’s List of Essential Medicines. While prices vary by pharmacy and insurance coverage, it is one of the most affordable treatments in the lupus medication arsenal, which is part of why guidelines recommend it as first-line therapy for all patients.
